Vemurafenib: The road to personalized medicine in melanoma

Drugs of Today

Volumn 48, Issue 2, 2012, Pages 109-118

  Amaria, R N ^a   Lewis, K D ^a   Jimeno, Antonio ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

BRAF; Melanoma; Targeted therapy; Vemurafenib

Indexed keywords

ANTIRETROVIRUS AGENT; B RAF KINASE; CARBAMAZEPINE; DACARBAZINE; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; ONDANSETRON; PHENOBARBITAL; PHENYTOIN; PLX 4720; PYRROLE DERIVATIVE; RIFAMPICIN; UNCLASSIFIED DRUG; VEMURAFENIB; WARFARIN;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; ENZYME PHOSPHORYLATION; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; IRITIS; KERATOACANTHOMA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; METASTASIS; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; SURVIVAL TIME; THYROID PAPILLARY CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VOMITING;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; INDIVIDUALIZED MEDICINE; INDOLES; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84858207885     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.2.1745274     Document Type: Review

References (33)

1. Jemal, A., Saraiya. M., Patel, P. et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 2011, 65(5 Suppl. 1): S17-S25.e3.
2. th Edition. Edge, S.B., Byrd, D.R., Compton, C.C. et al. (Eds). Springer Press: New York 2010, 387-415.
3. Agarwala, S.S. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009, 9(5): 587-95.
4. Atkins, M.B., Lotze, M.T., Dutcher, J.P. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17(7): 2105-16. (Pubitemid 29318842)
5. Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8): 711-23.
6. Inamdar, G.S., Madhunapantula, S.V., Robertson, G.P. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol 2010, 80(5): 624-37.
7. Davies, H., Bignell, G.R., Cox, C. et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892): 949-54. (Pubitemid 34716871)
8. McCubrey, J.A., Abrams, S.L., Ligresti, G. et al. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008, 22(11): 2080-90.
9. Wu, J., Rosenbaum, E., Begum, S. et al. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol 2007, 29(6): 534-7. (Pubitemid 350158863)
10. Bauer. J., Büttner, P., Murali, R., Westra, W.H. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011, 24(2): 345-51.
11. Long, G.V., Menzies, A.M., Nagrial, A.M. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011, 29(10): 1239-46.
12. Panka, D.J., Wang, W., Atkins, M.B., Mier, J.W. The Raf inhibitor BAY 43-9006 (sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006, 66(3): 1611-9. (Pubitemid 43259945)
13. Eisen, T., Ahmad, T., Flaherty, K.T. et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95(5): 581-6. (Pubitemid 44325897)
14. Eisen, T., Marais, R., Affolter, A. et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer 2011, 105(3): 353-9.
15. Tsai, J., Lee, J.T., Zhang, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008, 105(8): 3041-6. (Pubitemid 351723664)
16. FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer [news release]. U.S. Food and Drug Administration, August 17, 2011.
17. th Annu Meet Am Assoc Cancer Res (ASCO) (June 3-7, Chicago) 2011] 2011, 29(Suppl. 15): Abst 10523.
18. Hingorani, S.R., Jacobetz, M.A., Robertson, G.P., Herlyn, M., Tuveson, D.A. Suppression of BRAF(V599E) in human mela- noma abrogates transformation. Cancer Res 2003, 63(17): 5198-02.
19. Søndergaard, J.N., Nazarian, R., Wang, Q. et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010, 8: 39-50.
20. Yang, H., Higgins, B., Kolinsky, K. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010, 70(13): 5518-27.
21. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 363(9): 809-19.
22. ZELBORAF (vemurafenib) package insert. Genentech USA, 2011.
23. Bollag, G., Hirth, P., Tsai, J. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467(7315): 596-9.
24. th Annu Meet Am Assoc Cancer Res (ASCO) (June 3-7, Chicago) 2011] 2011, 29(Suppl. 15): Abst 8509.
25. Chapman, P.B., Hauschild, A., Robert, C. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26): 2507-16.
26. th Int Cong Soc Melanoma Res (Nov 9-11, Tampa) 2011] 2011, 24(5): Abst LBA1-2.
27. Sosman, J.A., Kim, K.B., Schuchter, L. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8): 707-14.
28. th Int Cong Soc Melanoma Res (Nov 9-11, Tampa) 2011] 2011, 24(5): Abst JIV-2.
29. Dubauskas, Z., Kunishige, J., Prieto, V.G., Jonasch, E., Hwu, P., Tannir, N.M. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009, 7(1): 20-3.
30. Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468(7326): 968-72.
31. Nazarian, R., Shi H., Wang Q. et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468(7326): 973-9.
32. Wagle, N., Emery, C., Berger, M.F. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011, 29(22): 3085-96.
33. Boni, A., Cogdill, A.P., Dang, P. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010, 70(13): 5213-9.